Caris Life Sciences, Inc. reported third-quarter revenue of $275.4 million, up 27% year-over-year, with adjusted EBITDA of $44.4 million and GAAP net income of $15.3 million. Management raised full-year revenue guidance to $1.04 billion to $1.05 billion.
CAI · Caris Life Sciences, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Caris reported nine-month revenue of $755.2 million, up 45.5% from $519.1 million, and net income of $14.1 million versus a $(150.0) million loss. Third-quarter revenue rose 27.0% to $275.4 million, while net income fell to $15.3 million from $24.3 million.
Caris Life Sciences reported results for the quarter ended September 30, 2026: total revenue of $275.4 million, up 27%, and net income of $15.3 million. Full-year 2026 revenue guidance raised to $1.04 to $1.05 billion, growth of 28% to 29%.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 4, 2026TL;DR. Revenue rose 27%, clinical cases rose 21%, and 2026 guidance increased to $1.04 to $1.05 billion; Caris also remained profitable and launched monitoring ahead of a targeted MRD launch. Gross margin contracted, net income and adjusted EBITDA were below prior-year levels, operating expenses increased, free cash flow was negative, and FDA approval is not near term for Caris Detect.
- + Full-year 2026 revenue guidance was raised to $1.04 to $1.05 billion, representing 28% to 29% growth.
- + Third-quarter revenue increased 27% year over year to $275.4 million.
- + Clinical case volume increased approximately 21% year over year to approximately 61,500 cases.
- + Caris generated $44.4 million of adjusted EBITDA and returned to GAAP profitability with $15.3 million of net income.
- + Caris launched therapy-response monitoring and targeted Caris Confirm for launch before year-end.
- + The preliminary 2027 clinical lab fee schedule increased the Caris Assure rate to $5,250 from $3,650.
- − Gross margin declined to 66% from 68% in the prior-year quarter.
- − GAAP net income declined to $15.3 million from $24.3 million in the prior-year quarter.
- − Operating expenses increased 42% year over year to $163.0 million.
- − Third-quarter free cash flow was negative $39.7 million.
- − Third-quarter adjusted EBITDA declined to $44.4 million from $51.2 million in the prior-year quarter.
- − An FDA pathway for Caris Detect is not in the near-term future.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $55.7M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net loss -637K
-6.82M Interest income
+9.23M Interest expense
+0K Changes in fair value of financial instruments
+25.13M Other expense, net
+23K Income tax expense (benefit)
+6.54M Depreciation and amortization expense
+22.22M Stock-based compensation expense
= Adjusted EBITDA 55.68M
|
|||
| Caris Assure cases | 10,700 | Q2 2026 | — |
| Clinical cases | 59,200 | Q2 2026 | +18.4% |
|
|
|||
| Free cash flow non-GAAP | $6.4M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by (used in) operating activities 28.48M
-22.08M Less: capitalized software and purchases of property and equipment
= Free cash flow 6.4M
|
|||
| MI Profile cases | 48,300 | Q2 2026 | — |
| Revenue from clinical cases for patients covered by Medicare | 38.9% | the three months ended June 30, 2026 filing | — |
| Share repurchase program (remaining authorization) | $82.1M | as of August 5, 2026 | — |
| Total matched profiles | 845,000 | through June 30, 2026 | — |
| Total oncology tests | 345,000 | Q2 2026 | — |
| Total profiles | 1,130,000 | through June 30, 2026 | — |
| Whole exome profiles | 733,000 | through June 30, 2026 | — |
| Whole exome/whole transcriptome tests | 114,000 | Q2 2026 | — |
| Whole transcriptome profiles | 783,000 | through June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CAI
this stock
Caris Life Sciences, Inc.
|
$5.32B | -31.3% | +97.0% | 55.4 | 4.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 4, 2026
- This year
- 18
Caris reported nine-month revenue of $755.2 million, up 45.5% from $519.1 million, and net income of $14.1 million versus a $(150.0) million loss. Third-quarter revenue rose 27.0% to $275.4 million, while net income fell to $15.3 million from $24.3 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CAI | -22.6% | -41.5% | +12.7% | -46.0% | -31.3% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -17.2% | -35.2% | +18.3% | -40.7% | -36.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.